Earl Elizabeth R, Waterston Mary M, Aughey Elizabeth, Harvey Michael J A, Matschke Christian, Colston Angela, Ferro Valerie A
Novartis Animal Vaccines Ltd., Springwood Industrial Estate, Braintree, Essex CM7 2YW, UK.
Vaccine. 2006 Apr 12;24(16):3172-83. doi: 10.1016/j.vaccine.2006.01.041. Epub 2006 Feb 2.
A modified GnRH peptide (CHWSYGLRPG-NH(2)) was conjugated to tetanus toxoid (TT) or diphtheria toxoid (DT) and formulated with Quil A saponin or a sustained release injectible PLGA (poly(lactide-co-glycolide)/triacetin). For the Quil A formulations, two administrations of TT conjugate at 3-weekly intervals were followed by two booster injections with the DT conjugate in entire ram lambs. With the PLGA formulations, only two injections were administered; the first containing TT and the second DT at 6-weekly intervals. Evaluation was carried out by comparing the specific antibody levels produced in relationship to hormone profiles and testicular changes. The Quil A formulation was considered the most effective, as it caused significant reduction in testosterone and follicle stimulating hormone levels, resulting in marked suppression of spermatogenesis.
一种修饰的促性腺激素释放激素肽(CHWSYGLRPG-NH₂)与破伤风类毒素(TT)或白喉类毒素(DT)偶联,并与Quil A皂苷或缓释注射用聚丙交酯-乙交酯(PLGA)/三醋精配制。对于Quil A制剂,在全部成年公羊中,每3周间隔两次注射TT偶联物,随后两次注射DT偶联物作为加强免疫。对于PLGA制剂,仅进行两次注射;第一次注射含TT,第二次注射含DT,间隔6周。通过比较与激素水平和睾丸变化相关的特异性抗体水平进行评估。Quil A制剂被认为是最有效的,因为它能显著降低睾酮和促卵泡激素水平,从而明显抑制精子发生。